• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » University of Oklahoma, Sarah Cannon Partner on Early-Stage Cancer Research

University of Oklahoma, Sarah Cannon Partner on Early-Stage Cancer Research

March 8, 2010
CenterWatch Staff

The University of Oklahoma’s OU Cancer Institute (OUCI) is partnering with strategic research organization Sarah Cannon Research Institute (SCRI) to expand the school’s early-phase oncology clinical trials program.

Founded nearly 10 years ago, OUCI wanted to expand its work in early-stage trials, said OUCI’s director Robert Mannel, M.D. OUCI is currently conducting more than 100 research projects supported by $20 million in funding from sponsors including the National Institutes of Health, the National Cancer Institute and the American Cancer Society.

“What we wanted to do was expand into earlier pharma-sponsored trials—particularly first-in-human phase I or phase Ib—that were directed toward some of our strengths,” Mannel said.

SCRI offers management, regulatory and other support services to sponsors and investigative sites. The company conducts community-based clinical trials in cardiology, oncology, gastroenterology and other therapeutic areas through affiliations with a network of more than 450 physicians in 25 states. OUCI is the first academic affiliation in SCRI’s network.

“We found the ideal partner in Sarah Cannon in that Sarah Cannon has a good working relationship with a number of pharmaceutical industry [people] and [they] actually do a fair number of investigator-initiated trials through their network,” Mannel said.

SCRI will provide research and clinical trials management services to help OUCI with regulatory and safety compliance, as well as technology and tools to improve trial quality and protocol adherence. OUCI physicians and staff will work with SCRI’s physicians and clinical research team, both at the University of Oklahoma and at SCRI’s headquarters in Nashville, Tenn.

“We are pleased to work with OUCI because of their prominent reputation for research in women’s gynecologic cancers,” said SCRI’s CEO Dee Anna Smith. “We’re able to further enhance our research in that area while providing OUCI phase I trials and clinical trials management services that benefit their program.”

As part of its efforts to step up the university’s early-stage work, Mannel said, OUCI has also reworked its internal structure for early-stage trials to be more efficient and effective.

“We’ve convinced the university hierarchy that, in order to be responsive and to be innovative and to have access to the newest agents, we have to not be bogged down in a university bureaucracy that is not responsive and is too slow to get trials activated and initiated for our patients,” he said. “Our vision is what Sarah Cannon’s philosophy is and that is, from when an agreement with a company is made to [when a trial begins should take] six weeks or less. I think that is a very reasonable and realistic goal, and we’re holding ourselves to that. We’re learning from Sarah Cannon to be better at the business end.”

OUCI started its first trial with SCRI in February and hopes to be running at least 35 trials and placing 100 patients annually by the end of the year.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing